Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Policy developments in regulatory approval.

Robert Temple1

  • 1Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA. temple@cder.fda.gov

Statistics in Medicine
|September 27, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Closing the gap: A United States perspective on enhancing drug evaluation in older adults.

Journal of the American Geriatrics Society·2024
Same author

Participation of Older Adults in Clinical Trials for New Drug Applications and Biologics License Applications From 2010 Through 2019.

JAMA network open·2022
Same author

Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants: A Randomized Clinical Trial.

JAMA network open·2022
Same author

Roadmap to 2030 for Drug Evaluation in Older Adults.

Clinical pharmacology and therapeutics·2021
Same author

U.S. racial and ethnic participation in global clinical trials by therapeutic areas.

Journal of clinical pharmacy and therapeutics·2021
Same author

Encouragement of subgroup assessment by the FDA.

Pharmaceutical statistics·2021
Same journal

A Mixture of Distributed Lag Non-Linear Models to Account for Spatially Heterogeneous Exposure-Lag-Response Associations.

Statistics in medicine·2026
Same journal

Practical Considerations for Gaussian Process Modeling for Causal Inference in Quasi-Experimental Studies With Panel Data.

Statistics in medicine·2026
Same journal

Covariate Adjustment for Wilcoxon Two Sample Statistic and Test.

Statistics in medicine·2026
Same journal

Beyond Fixed Thresholds: Optimizing Summaries of Wearable Device Data via Piecewise Linearization of Quantile Functions.

Statistics in medicine·2026
Same journal

A Causal Framework for Evaluating the Total Effect of Strategies Aiming to Expand Screening and to Improve Outcomes.

Statistics in medicine·2026
Same journal

Causal Effects on Nonterminal Event Time With Application to Antibiotic Usage and Future Resistance.

Statistics in medicine·2026
See all related articles

Drug regulation evolves with new laws like the Food and Drug Administration Modernization Act (FDAMA), impacting trial design and approval standards. Key changes address surrogate endpoints, control groups, and subgroup analysis for safer drug development.

Area of Science:

  • Pharmaceutical Sciences
  • Regulatory Affairs
  • Clinical Trial Design

Background:

  • Drug regulation undergoes gradual evolution rather than radical change.
  • Recent regulatory shifts are influenced by legislation, international harmonization, safety concerns, and ethical considerations.

Purpose of the Study:

  • To outline the significant evolving trends in drug regulation and guidance.
  • To highlight the impact of recent legislative and ethical factors on drug approval processes.

Main Methods:

  • Review of legislative acts, including the Food and Drug Administration Modernization Act (FDAMA).
  • Analysis of International Conference on Harmonization (ICH) guidelines.
  • Examination of trends in clinical trial design, data reliance, and risk management.

Related Experiment Videos

Main Results:

  • FDAMA and related guidance have clarified criteria for using single studies and surrogate endpoints for drug approval.
  • ICH guidelines emphasize ethical considerations for placebo controls and the design of non-inferiority trials.
  • Increased focus on dose-response data, subgroup analyses (demographics, disease states), drug-drug interactions, and risk management strategies.

Conclusions:

  • Drug regulatory frameworks are adapting to new challenges, emphasizing robust evidence generation and risk mitigation.
  • Modern drug development increasingly incorporates global data, collaborative meetings, and comprehensive safety assessments.